|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.070 USD | -1.69% |
|
-5.57% | -39.97% |
Business description: Cadrenal Therapeutics, Inc.
Number of employees: 5
Sales by Activity: Cadrenal Therapeutics, Inc.
| Fiscal Period: December | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Geographical breakdown of sales: Cadrenal Therapeutics, Inc.
| Fiscal Period: December | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Executive Committee: Cadrenal Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Quang Pham
CEO | Chief Executive Officer | 61 | 2022-01-24 |
Jeffrey Cole
COO | Chief Operating Officer | 58 | 2024-02-05 |
James Ferguson
CTO | Chief Tech/Sci/R&D Officer | 72 | 2025-02-05 |
Matthew Boxer
PRN | Corporate Officer/Principal | - | - |
Composition of the Board of Directors: Cadrenal Therapeutics, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
John Murphy
BRD | Director/Board Member | 76 | 2023-01-18 |
| Director/Board Member | 67 | 2023-01-18 | |
Glynn Wilson
BRD | Director/Board Member | 78 | 2023-01-18 |
Quang Pham
CHM | Chairman | 61 | 2022-01-24 |
Lee Golden
BRD | Director/Board Member | 59 | 2025-11-23 |
Company details: Cadrenal Therapeutics, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.69% | -5.57% | -72.87% | -82.83% | 12.74M | |
| +1.65% | +6.42% | +53.16% | +109.62% | 54.82B | |
| +0.03% | -1.80% | +49.57% | +43.94% | 43.27B | |
| +2.79% | -0.99% | -15.89% | -19.21% | 21.79B | |
| +5.04% | -7.64% | -1.10% | +396.92% | 19.92B | |
| +0.81% | -8.38% | +12.77% | -33.24% | 15.67B | |
| +0.53% | +2.08% | +8.89% | -40.13% | 15.26B | |
| +1.35% | +1.57% | +28.69% | +179.28% | 13.22B | |
| -5.27% | +3.89% | +90.88% | +208.02% | 11.58B | |
| -1.74% | -1.05% | +12.88% | - | 11.94B | |
| Average | +0.32% | -0.64% | +16.70% | +84.71% | 20.75B | |
| Weighted average by Cap. | +0.98% | +1.16% | +31.86% | +97.38% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVKD Stock
- Company Cadrenal Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
